Gorrissen Federspiel has assisted Adcendo with an oversubscribed Series C funding round of USD 75M.
The financing round was led by JEITO Capital, with participation from additional new investors Vida Ventures, BPI France, and EIFO (Export and Investment Fund of Denmark), as well as all existing investors, including TCGX, RA Capital Management, TPG, Orbimed, Venrock, Surveyor, Logos Capital, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, a platform controlled by KKR, HealthCap, Gilde Healthcare and Ysios Capital.
Adcendo, is a biotech company focused on the development of first-and best-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need.
Proceeds from the fundraise will be used to support Adcendo through multiple upcoming key clinical milestones from the Company’s ADC pipeline.
We congratulate Adcendo and their investors on the successful investment.
The core team from Gorrissen Federspiel consisted of Niels Bang, Caroline Helene Krestine Boysen, and Andreas Nystrup Hoxer Gregersen.